Skip to main content

Table 3 Association between NCAPG expression and clinicopathologic characteristics of LUAD patients

From: NCAPG promotes the progression of lung adenocarcinoma via the TGF-β signaling pathway

Clinical characteristics NCAPG p-value
Low expression High expression
Age (y)
 ≥ 65 74 86 0.407
 < 65 54 78
Sex
 Male 63 87 0.556
 Female 65 77
Clinical stage
 I 79 71 0.004
 II 28 44
 III & IV 21 49
T classification
 T1 47 41 0.091
 T2 66 98
 T3 & T4 15 25
N classification
 N0 92 92 0.006
 N1 & N2 & N3 36 72
Metastasis
 No 125 148 0.011
 Yes 3 16
  1. T for extent of the primary tumor; N for involvement of lymph nodes
  2. T1: Tumor ≤ 3 cm; T2: Tumor > 3 but ≤ 5 cm or tumor involving visceral pleura, main bronchus (not carina), atelectasis to hilum; T3: Tumor > 5 but ≤ 7 cm or invading chest wall, pericardium, phrenic nerve or or separate tumor nodule(s) in the same lobe; T4: Tumor > 7 cm or tumor invading: mediastinum, diaphragm, heart, great vessels, recurrent laryngeal nerve, carina, trachea, esophagus, spine or tumor nodule(s) in a different ipsilateral lobe
  3. N0: No regional node metastasis; N1: Metastasis in ipsilateral pulmonary or hilar nodes; N2: Metastasis in ipsilateral mediastinal/subcarinal nodes; N3: Metastasis in contralateral mediastinal/hilar, or suprclavicular nodes